A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects
Status:
COMPLETED
Trial end date:
2025-01-09
Target enrollment:
Participant gender:
Summary
IBI128 (Tigulixostat) is a novel non-purine selective inhibitor of xanthine oxidase (XO). The XO inhibitors lower uric acid concentrations in serum by inhibiting the production of uric acid.
This ia a randomized, open label, multicenter, parallel-group, positive-controlled, dose finding, and Phase II study to assess efficacy and safety of IBI128 in chinese gout subjects.